MX344663B - Medicamento dirigido a tumor derivado de combretastatina a4. - Google Patents

Medicamento dirigido a tumor derivado de combretastatina a4.

Info

Publication number
MX344663B
MX344663B MX2013015120A MX2013015120A MX344663B MX 344663 B MX344663 B MX 344663B MX 2013015120 A MX2013015120 A MX 2013015120A MX 2013015120 A MX2013015120 A MX 2013015120A MX 344663 B MX344663 B MX 344663B
Authority
MX
Mexico
Prior art keywords
targeted drug
tumor targeted
derivative
acid ester
derivatives
Prior art date
Application number
MX2013015120A
Other languages
English (en)
Other versions
MX2013015120A (es
Inventor
Wang Yong
Zhang Cang
Liu Xiaorong
Zhang Yan
Wang Yunyun
Zhang Wenping
Original Assignee
Nanjing Sanhome Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Sanhome Pharmaceutical Co Ltd filed Critical Nanjing Sanhome Pharmaceutical Co Ltd
Publication of MX2013015120A publication Critical patent/MX2013015120A/es
Publication of MX344663B publication Critical patent/MX344663B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Abstract

La presente invención se relaciona a derivados de imidazol, oxazol de combretastatina A4 de fármacos que atacan los tumores, y ésteres de fosfato, ésteres de sulfonato o sales farmacéuticamente aceptables, derivados de glicósidos, solvatos de los mismos, en donde el anillo A comprende un grupo 3,5-dimetoxifenilo que tiene un sustituto en la posición 4. Los ensayos de la actividad farmacológica han demostrado que los compuesto de la presente invención tienen buena actividad anti-tumor in vitro y excelente efecto inhibitorio de tubulina.
MX2013015120A 2011-07-05 2012-07-04 Medicamento dirigido a tumor derivado de combretastatina a4. MX344663B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110186688 2011-07-05
CN201110422678.5A CN102863388B (zh) 2011-07-05 2011-12-16 肿瘤靶向药物Combretastatin A4衍生物
PCT/CN2012/000921 WO2013004075A1 (zh) 2011-07-05 2012-07-04 肿瘤靶向药物Combretastatin A4衍生物

Publications (2)

Publication Number Publication Date
MX2013015120A MX2013015120A (es) 2014-10-17
MX344663B true MX344663B (es) 2017-01-04

Family

ID=47436477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015120A MX344663B (es) 2011-07-05 2012-07-04 Medicamento dirigido a tumor derivado de combretastatina a4.

Country Status (10)

Country Link
US (1) US9139574B2 (es)
EP (1) EP2730565B1 (es)
JP (1) JP5875679B2 (es)
KR (1) KR101579093B1 (es)
CN (1) CN102863388B (es)
AU (1) AU2012278750B2 (es)
BR (1) BR112013033452A2 (es)
CA (1) CA2839942C (es)
MX (1) MX344663B (es)
WO (1) WO2013004075A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105753787B (zh) * 2011-07-05 2018-05-15 南京圣和药业股份有限公司 肿瘤靶向药物Combretastatin A4衍生物
CN104418821A (zh) * 2013-08-22 2015-03-18 四川大学华西医院 2,4位取代的5-(3,4,5-三甲氧基苯基)噻唑衍生物及其制备方法和用途
CN104771371B (zh) * 2014-01-14 2021-02-19 南京圣和药业股份有限公司 4-(3,5-二甲氧苯基)-5-(3-羟基-4-甲氧基苯基)咪唑制剂
CN104771396B (zh) * 2014-01-14 2019-04-26 南京圣和药业股份有限公司 4-(3,5-二甲氧苯基)-5-(3-羟基-4-甲氧基苯基)咪唑的应用
CN105017325A (zh) * 2014-04-18 2015-11-04 南京圣和药业股份有限公司 二苯基咪唑类抗癌药物晶型d及其制备方法
CN105017322B (zh) * 2014-04-18 2018-09-28 南京圣和药业股份有限公司 二苯基咪唑类抗癌药物的制备方法
CN105017324A (zh) * 2014-04-18 2015-11-04 南京圣和药业股份有限公司 二苯基咪唑类抗癌药物晶型n及其制备方法
CN105017323A (zh) * 2014-04-18 2015-11-04 南京圣和药业股份有限公司 二苯基咪唑类抗癌药物晶型a及其制备方法
CN105017321A (zh) * 2014-04-18 2015-11-04 南京圣和药业股份有限公司 二苯基咪唑类抗癌药物晶型及其制备方法
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
CN109453123B (zh) * 2018-11-19 2021-05-11 中国药科大学 一种康普瑞汀类衍生物冻干粉针及其制备方法
CN111116571B (zh) * 2019-12-27 2022-07-12 吉首大学 含恶唑及三唑双杂环的化合物及其制备与应用方法
WO2022236253A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
US6201001B1 (en) * 1999-08-02 2001-03-13 Abbott Laboratories Imidazole antiproliferative agents
CA2432640A1 (en) * 2000-12-21 2002-06-27 Cancer Research Technology Limited Substituted stilbenes, their reactions and anticancer activity
ITRM20030355A1 (it) * 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
CN101130539B (zh) * 2007-09-26 2012-05-30 浙江大学 吲哚取代咪唑啉-2-酮类衍生物及其制备方法和用途
CN101230074A (zh) 2008-01-29 2008-07-30 中国海洋大学 噁唑类化合物的磷酸盐衍生物及其制备方法
CN101230079A (zh) 2008-01-29 2008-07-30 中国海洋大学 噁唑类化合物的1,2-反式糖苷衍生物及其制备方法
CN101602730B (zh) * 2008-06-12 2013-06-19 北大方正集团有限公司 取代的咪唑衍生物
WO2010132498A1 (en) * 2009-05-11 2010-11-18 Oxigene, Inc. Vascular disrupting agents for treatment of polypoidal choroidal vasculopathy
CN102190625B (zh) 2010-03-18 2013-08-28 南京圣和药业有限公司 二苯乙烯类肿瘤靶向药物Combretastatin A4类似物
EP2566851B1 (en) * 2010-05-05 2015-01-14 Universität Bayreuth Combretastatin analogs for use in the treatment of cancer

Also Published As

Publication number Publication date
CA2839942A1 (en) 2013-01-10
US9139574B2 (en) 2015-09-22
AU2012278750A1 (en) 2014-01-30
US20140128384A1 (en) 2014-05-08
EP2730565A1 (en) 2014-05-14
EP2730565A4 (en) 2015-04-29
CN102863388A (zh) 2013-01-09
MX2013015120A (es) 2014-10-17
BR112013033452A2 (pt) 2017-10-31
AU2012278750B2 (en) 2015-03-05
KR20140044878A (ko) 2014-04-15
CA2839942C (en) 2016-10-11
EP2730565B1 (en) 2017-04-26
JP5875679B2 (ja) 2016-03-02
CN102863388B (zh) 2015-04-29
KR101579093B1 (ko) 2015-12-21
JP2014523885A (ja) 2014-09-18
WO2013004075A1 (zh) 2013-01-10

Similar Documents

Publication Publication Date Title
MX344663B (es) Medicamento dirigido a tumor derivado de combretastatina a4.
PH12014502733A1 (en) Neprilysin inhibitors
MY165087A (en) Neprilysin inhibitors
PH12015500260A1 (en) Neprilysin inhibitors
ECSP12012111A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
IN2015DN00185A (es)
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
MY163083A (en) Solid forms of a pharmaceutically active substance
CR20140301A (es) Derivados de betulina
MX342212B (es) Inhibidores de neprilisina.
MY170935A (en) Neprilysin inhibitors
WO2013038429A3 (en) Novel sglt inhibitors
MX2013010511A (es) Inhibidores triciclicos de girasa.
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
SG191175A1 (en) Neprilysin inhibitors
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
IN2014CN03803A (es)
MY187718A (en) Pharmaceutical formulations
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
WO2012172566A3 (en) Novel sglt inhibitors
MY160392A (en) Triptolide prodrugs
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
IN2014DN01629A (es)

Legal Events

Date Code Title Description
FG Grant or registration